By Sabela Ojea

Eiger BioPharmaceuticals said it is discontinuing the company's phase 3 study to treat peginterferon lambda in patients with chronic hepatitis delta and has ceased active discussions for a worldwide license of the treatment.

The commercial-stage biopharmaceutical company said its decision is based on the Data Safety Monitoring Board, which recommended the discontinuation following a quarterly safety review.

Four patients with hepatobiliary events resulted in liver decompensation during the LIMT-2 study, the company said.

"We will work closely with the Food and Drug Administration and our investigators to conduct an orderly termination of the LIMT-2 study in the interest of patient safety," Chief Executive David Apelian added.

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

(END) Dow Jones Newswires

September 12, 2023 17:02 ET (21:02 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Eiger BioPharmaceuticals (NASDAQ:EIGR)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024 Eiger BioPharmaceuticals 차트를 더 보려면 여기를 클릭.
Eiger BioPharmaceuticals (NASDAQ:EIGR)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024 Eiger BioPharmaceuticals 차트를 더 보려면 여기를 클릭.